Zacks Research Has Pessimistic View of TBPH FY2024 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research lowered their FY2024 earnings per share estimates for Theravance Biopharma in a research note issued to investors on Tuesday, December 3rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($1.06) for the year, down from their previous estimate of ($0.97). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.06) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.88 EPS, FY2025 earnings at $0.07 EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at $0.08 EPS and FY2026 earnings at $0.58 EPS.

Several other analysts have also recently commented on the stock. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Theravance Biopharma presently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $9.88 on Friday. The firm has a market cap of $485.80 million, a PE ratio of -9.78 and a beta of 0.23. The firm has a 50 day simple moving average of $8.86 and a 200-day simple moving average of $8.72. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter in the prior year, the business posted ($0.17) EPS.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC grew its stake in Theravance Biopharma by 279.9% during the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 48,316 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Theravance Biopharma during the 3rd quarter valued at $251,000. XTX Topco Ltd boosted its position in Theravance Biopharma by 34.5% during the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 5,243 shares during the period. Jane Street Group LLC increased its holdings in Theravance Biopharma by 1.1% in the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 1,640 shares in the last quarter. Finally, PDT Partners LLC raised its position in Theravance Biopharma by 31.2% in the third quarter. PDT Partners LLC now owns 87,177 shares of the biopharmaceutical company’s stock valued at $703,000 after purchasing an additional 20,738 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at $2,904,687. This trade represents a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.